BIOMARKER:

Chr rearrangement(11)(q23)

Chr rearrangement(11)(q23) Chr rearrangement(11)(q23)	Acute Myelogenous Leukemia AML	Chr rearrangement(11)(q23) Chr rearrangement(11)(q23)	Acute Myelogenous Leukemia AML	cytarabine/daunorubicin liposomal formulation Resistant: C3 – Early Trials	cytarabine / daunorubicin liposomal formulation Resistant: C3 – Early Trials
Chr rearrangement(11)(q23) Chr rearrangement(11)(q23)	Acute Myelogenous Leukemia AML	Chr rearrangement(11)(q23) Chr rearrangement(11)(q23)	Acute Myelogenous Leukemia AML	cytarabine Resistant: C3 – Early Trials	cytarabine Resistant: C3 – Early Trials

Associations